Another Oncology Deal for Sanofi
By Taskin Ahmed
PharmaDeals Review: Vol 2009 Issue 6 (Table of Contents)
Published: 23 Jun-2009
DOI: 10.3833/pdr.v2009i6.1125 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Sanofi-aventis and Exelixis have entered into a license agreement for XL147 and XL765 and a collaboration to develop inhibitors of phosphoinositide-3 kinase (PI3K) to treat cancer...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login on the top right purple box.
Copyright: PharmaVentures Ltd
RSS